Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 2 |
Descriptor
| Comparative Analysis | 2 |
| Drug Therapy | 2 |
| Medical Research | 2 |
| Meta Analysis | 2 |
| Network Analysis | 2 |
| Outcomes of Treatment | 2 |
| Patients | 2 |
| Accuracy | 1 |
| Bayesian Statistics | 1 |
| Clinical Diagnosis | 1 |
| Data Analysis | 1 |
| More ▼ | |
Source
| Research Synthesis Methods | 2 |
Author
| Leahy, Joy | 2 |
| Walsh, Cathal | 2 |
| Afdhal, Nezam | 1 |
| Gray, Emma | 1 |
| Milligan, Scott | 1 |
| O'Leary, Aisling | 1 |
| Wehmeyer, Malte H. | 1 |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkLeahy, Joy; Walsh, Cathal – Research Synthesis Methods, 2019
If IPD is available for some or all trials in a network meta-analysis (NMA), then incorporating this IPD into an NMA is routinely considered to be preferable. However, the situation often arises where a researcher has IPD for trials concerning a particular treatment (eg, from a sponsor) but none for other trials. Therefore, one can reweight the…
Descriptors: Comparative Analysis, Meta Analysis, Bayesian Statistics, Network Analysis
Leahy, Joy; O'Leary, Aisling; Afdhal, Nezam; Gray, Emma; Milligan, Scott; Wehmeyer, Malte H.; Walsh, Cathal – Research Synthesis Methods, 2018
The use of individual patient data (IPD) in network meta-analysis (NMA) is becoming increasingly popular. However, as most studies do not report IPD, most NMAs are performed using aggregate data for at least some, if not all, of the studies. We investigate the benefits of including varying proportions of IPD studies in an NMA. Several models have…
Descriptors: Patients, Medical Research, Meta Analysis, Network Analysis
